Immunization of mice with a synthetic peptide that corresponds to a murine antibody-defined immunodominant domain of herpes simplex virus (HSV) glycoprotein D (gD) induced neutralizing antibodies against HSV types 1 and 2 and protected animals against a lethal challenge with HSV type 2 (Dietzschold, B., Eisenberg, R., Ponce de Leon, M., Golub, E., Hudecz, F., Varicchio, A. & Cohen, G. (1984) J. Virol. 52,[431][432][433][434][435]. We report here that human peripheral blood T cells from HSV-seropositive and -seronegative adult donors are activated by this synthetic peptide in vitro. Interleukin-2-dependent T-cell lines established from these cultures respond specifically to peptides containing residues 1-23 of HSV gD and to a panel of overlapping peptides within this domain. The T-cell proliferative response was maximal when the majority of interleukin-2-propagated T cells were of the helper phenotype and the peptides were at least 16 amino acids long. Peptides of 8 or 12 amino acids from the carboxyl terminus were nonstimulatory. Peptide-activated T-cell lines from seronegative donors less than 11 years old could be established in vitro, but most cells were of the suppressor/cytotoxic phenotype and demonstrated no antigen-specificity when tested with the panel of synthetic peptides.
The immune response to herpes simplex virus (HSV) has been shown to involve a variety of effector mechanisms which include production of virus-neutralizing antibody, cytotoxic T lymphocytes, natural killer (NK) cells, antibodydependent cellular cytotoxicity, and T-cell-derived lymphokines (43) . The pivotal role of helper T-cells in the induction of these responses has been well documented (44, 45) .
The nature of the HSV-specified antigens that act as immunostimulants has not been completely identified, but several lines of evidence implicate the major viral glycoproteins (1) . One of these, glycoprotein D (gD), has been shown to induce type-common viral-neutralizing antibody (2, 3) , and passive administration of monoclonal antibody (mAb) specific for gD protects mice from a lethal challenge with HSV (4). Moreover, gD appears to be recognized on HSV-infected cells by cytolytic effector cells (5) .
An antibody-defined immunodominant determinant of HSV type 1 (HSV-1) gD was localized and a peptide corresponding to residues 8-23 of the mature glycoprotein was synthesized. This peptide was recognized by an anti-gD mAb known to neutralize HSV-1 and -2 (6) . Moreover, immunization of mice with this synthetic molecule induces viral-neutralizing antibodies and confers protection against a lethal challenge with HSV-2 (7).
MATERIALS AND METHODS
Synthesis of HSV gD Peptides. Peptides were manually synthesized as described (6) by using the Merrifield solidphase method (8) . The completed peptides were simultaneously deprotected and cleaved from the resin with anhydrous HF containing thioanisole as an organic cation scavenger. The crude peptides were purified by gel filtration on Bio-Gel P-2 or P-4 (Bio-Rad) columns. Homogeneity of the peptides was demonstrated by thin-layer chromatography, amino acid analysis, and amino acid sequencing (9) . For thin-layer chromatography on Silica Gel 60-precoated aluminum sheets (Merck), two solvent systems were used: 1-butanol/acetic acid/water, 4:1:1 (vol/vol), or ethyl acetate/ pyridine/acetic acid/water, 60:20:6:11 (vol/vol); peptides were detected with ninhydrin or chlorine/toluidine.
Primary in Vitro Proliferation Assay. Whole blood was obtained by venipuncture from normal adult volunteers. Peripheral blood mononuclear cells (PBMC) were purified by density centrifugation on Lymphoprep (Nyegaard, Oslo), washed in Ca2 -and Mg2'-free Hanks' balanced salts solution, and seeded in microtiter plates (Costar, Cambridge, MA) at 3 x 105 per well in RPMI 1640 medium (M. A. Bioproducts, Walkersville, MD) plus 10% human AB serum (heat-inactivated), 2 mM glutamine, penicillin, and streptomycin (complete medium). Synthetic peptide 1-23, phytohemagglutinin (PHA; Burroughs Wellcome, Kent, England) at 1 ,ug/ml, or tetanus toxoid (Connaught Laboratories, Willowdale, ON) at 10 ,ug/ml were added to wells in triplicate. All cultures were incubated for 5 days at 5% C02; 1 ,uCi ( Induction of Synthetic Peptide-Activated T-Cell Lines. PBMC were isolated as described and suspended at 2 x 106 per ml in complete medium with synthetic peptide 1-23 at 100 ,ug/ml; 2 ml were seeded in each well of a 24-well cluster plate (Costar) and incubated at 37°C in 5% CO2. Cultures were fed twice weekly with complete medium, containing lectin-free, partially purified human interleukin 2 (IL-2) (Cellular Bioproducts, Buffalo, NY) at 10 units/ml, after large blastoid cells appeared.-For all donors tested in this study, this occurred between days 10 and 15. When viable blasts reached a concentration of 106 per ml, the nonadherent cells were removed from the plate, washed, resuspended at 105 per ml in complete medium with 5% lectin-free IL-2, and 50 ml was seeded in a T75 flask (Costar). Cells from all donors grew logarithmically for the next 10-14 days. At this time, T cells were restimulated with synthetic peptide 1-23, autologous y-irradiated PBMC (accessory cells), and lectin-free IL-2. All lines could be propagated indefinitely (>9 mo) with this protocol. At various times, cells were tested for specificity in a proliferation assay and for phenotype by flow cytometry.
Abbreviations: HSV, herpes simplex virus; gD, glycoprotein D; PBMC, peripheral blood mononuclear cell(s); IL-2, interleukin 2; mAb, monoclonal antibody; PHA, phytohemagglutinin; NK, natural killer.
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RESULTS
HSV gD Synthetic Peptides. To map antigenic epitopes within the NH2-terminal domain of gD that are recognized by T cells, we synthesized a series of overlapping peptides ranging in length from 7 to 23 amino acids and corresponding to the amino acid residues 1-23 of gD-1 or gD-2 (Table 1) . HSV-1-specific peptides were synthesized with alanine (A) in position 7 and aspartic acid (D) in position 21; HSV-2-specific peptides contain proline (P) and asparagine (N) in positions 7 and 21, respectively. Peptides 1-23(H) and 3-23(H) were synthesized to represent "hybrids" having the type 2-specific residue (proline) in position 7 and the type 1-specific residue (aspartate) in position 21.
Primary in Vitro Stimulation with Synthetic Peptide 1-23. We evaluated the proliferative response of PBMC from eight healthy adult donors, with or without serum antibody to HSV gD-1 and gD-2, to 1-23(H) ( Table 2 ). All donors showed minimal stimulation by 1-23(H) at all concentrations tested. The T-cell response to PHA of all donors was within normal range as was the response to tetanus toxoid. We observed no differences in the stimulation index to 1-23(H) which correlated with the presence of serum antibody to HSV gD-1 or gD-2.
If the relative nonresponsiveness to 1-23(H) was due to a low frequency of antigen-specific cells in the PBMC, we reasoned that expansion of antigen-stimulated PBMC in the presence of lectin-free IL-2 might result in establishment of synthetic peptide-specific T-cell lines. 
The single-letter amino acid abbreviations are used. Table 3 . Cell lines from all donors were >82% Leu-1-and >86% Leu-4-positive cells. Cell lines from most donors were predominantly of the Leu-3-positive (helper) subset, whereas donor D and donor G yielded Leu-2-positive (cytotoxic/suppressor) lines. NK cells as detected by Leu-7 were found in lower frequency than either T-cell subset.
Antigen-Induced Proliferative Response to Peptides of HSV gD. The T-cell lines from all donors were evaluated for their response to the synthetic peptides listed in Table 1 by measurement of proliferation after in vitro antigen challenge in the presence of autologous accessory cells. The T-cell lines from all donors responded to 1-23(H) in a dose-dependent fashion irrespective of the presence of serum HSV gD antibody in these donors. The recognition of synthetic peptide fragments varied among donors in that certain synthetic peptides were markedly stimulatory for one donor but not for another, as illustrated in Fig. 1 . (Fig. 1C) show a marginal response to 1-23(H) at 200 ,ug/ml but no response to any other synthetic peptide. Interestingly, this line is predominantly of Leu-2-positive (cytotoxic/suppressor) phenotype and was obtained from a donor with recurrent herpes facial labialis. The PHA stimulation index of this line was normal, indicating that the T cells are viable and mitogen-responsive. Fig. 2 illustrates the T-cell response of two seronegative donors. Fig. 2A (donor G) indicates that the most immunogenic peptides are those which have the three NH2-terminal amino acids possessed by the priming antigen, 1-23(H). Antigen concentration, pug/mi Those synthetic peptides without these determinants do not stimulate this line. Fig. 2B (donor F) indicates that synthetic peptide 1-16(2) (proline at position 7) is markedly stimulatory, whereas 1-16(1) (alanine at position 7) is not. Thus, this T-cell line appears capable of distinguishing a single amino acid substitution in this synthetic peptide fragment.
The patterns of reactivity for each donor were reproducible: repetitive blood samples obtained over a period of several months yielded peptide-specific T-cell lines which recognized the same determinants. These data suggest that the human T-cell response to these peptides may be controlled by immune response genes, as has been shown for random copolymers of amino acids (10) .
Since T-cell lines from all seronegative donors responded to 1-23(H) and at least one of its analogs, it was possible that either 1-23(H) was inducing a primary antigen-induced Tcell response in vitro or, alternatively, the absence of HSV gD serum antibody belies the fact that these individuals had encountered HSV previously. To address this question, we evaluated the ability of 1-23(H) to stimulate PBMC from seronegative children less than 11 years old with no clinical evidence of previous infection with HSV. Using the identical protocol as with the adults, IL-2-propagated lines were established, phenotyped, and tested for antigen-induced proliferation.
The phenotype of the IL-2-propagated lines from these children are shown in Table 4 . More than 92% of cells proliferating in response to IL-2 were Leu-1-positive. Leu-4, which detects peripheral T cells and NK cells, represented >97% of the population. More than 80% of T cells were of the Leu-2 (cytotoxic/suppressor) phenotype, whereas -15% were helper T cells (Leu-3-positive). NK cells, as detected by Leu-7 (11) and Leu-11 (12) represented 3.5-12.8%. Most of the T cells were DR-positive, as has been reported for activated T cells (13) . Leu-8-positive cells, which represent regulatory T cells in both the Leu-2 and Leu-3 populations, were also detected (14) .
When tested for antigen recognition, individual lines from all three children showed no response to any synthetic peptide at any concentration tested (up to 200 ,g/ml) ( (17) isolated a murine T-cell clone with specificity for a nine amino acid fragment from the same molecule.
Peptides of similar size have also been shown to be T-cell antigens. T cells from insulin B chain-primed guinea pigs recognize an octapeptide from that molecule (18) , whereas a nonapeptide of myelin basic protein is seen by T cells from guinea pigs with experimental allergic encephalomyelitis (19) . Similarly, murine T cells primed to myoglobin were stimulated in vitro by 13 -residue synthetic fragments of the molecule (20) .
HSV gD is a major structural antigen of the virus, which has been implicated in the induction of humoral and cell-mediated responses to the live virus and to virally infected and transformed cells (5, 21, 22) . Recently, the immunodominant domains of HSV gD have been mapped by using a panel of gD-specific mAbs (23) . Group VII mAbs identified a sequential or continuous determinant on gD and were capable of neutralizing live HSV-1 and -2 (23). Synthesis of overlapping peptides within this domain was undertaken in efforts toward the production of a type-common synthetic vaccine. A 16 amino acid synthetic peptide was identified which, when coupled to protein carriers, induced HSV type-common neutralizing antibody in mice and protected them against a lethal challenge of HSV-2 (6, 7). We report here that human T cells can be activated by and specifically recognize this synthetic peptide.
Although synthetic or purified sequenced peptides were stimulatory in vitro in the animal models previously cited, all animals used were previously primed in vivo with native antigen in adjuvants. Similarly, the human donors used by Lamb and co-workers to induce influenza virus hemagglutinin-specific T cells were specifically selected for their previous exposure to influenza as determined by serum antibody at high-titer (16, 24) . In contrast to these reports, we found that HSV gD peptide-specific T cells were generated from individuals who were not immunized in vivo to HSV as determined by their lack of serum antibody to HSV gD-1 or gD-2. Moreover, the T-cell lines generated from HSV-naive adult donors were qualitatively and quantitatively indistinguishable from those obtained from HSV-primed donors.
These findings may be the result of primary in vitro immunization with synthetic peptides. However, reports of in vitro immunization have been rare, presumably due to poor success. The exceptions have centered on in vitro antibody responses which rely on the addition of polyclonal activators (25) (26) (27) or antigens that have mitogenic activity (28) . Furthermore, native synthetic peptides have been found to be poor immunogens even in vivo, so that the induction of specific antibody in animals against these molecules has relied on the use of high molecular weight carriers coupled to them (7, 29, 30) . Our inability to generate specific T cells from children by using the same in vitro immunization protocol as with adults further argues that we are not inducing a primary immunization in vitro.
An alternate hypothesis is that the 16 amino acid sequences in these synthetic peptides mimic a sequence found in an HSV-unrelated antigen to which the adult donors, but not the children, have been exposed in vivo. Similar conclusions were reached by Hsu et al., who found a heterogenous T-cell proliferative response to the synthetic copolymer poly(LTyr, LGlu)-poly(DLAla)-poly(LLys) in adult but not Proc. Nad Acad ScL USA 82 (1985) Proc. NatL Acad ScL USA 82 (1985) 3429 neonatal PBMC (10) . Although the gD-analogous synthetic peptides were not mitogenic for peripheral-blood T cells from HSV-seronegative or -seropositive donors, continuous exposure to IL-2 and periodic stimulation with antigen expanded the 1-23 synthetic peptide-specific clones to the degree that both types of lines recognized synthetic peptides corresponding to sequences in this domain.
An implication of these results is that gD synthetic peptide 1-23 is a promising candidate for an HSV-directed vaccine in humans. The inability of the unmodified peptide to induce HSV-neutralizing antibody in mice does not diminish its vaccine potential, since there appears to be little correlation between the presence of HSV-neutralizing antibody and protection in humans. For example, killed whole-HSV vaccines that elicit neutralizing antibody in animals have not induced immune responses in HSV-naive humans. Virus-neutralizing antibodies, found in abundance in HSV carriers, do not affect the clinical course of recurrences (31) .
More recently, the role of T cells in the generation and persistence of cell-mediated immunity to HSV has been examined. Both protection against and recovery from HSV infections were shown to depend on the presence of I-regionrestricted helper T cells (32, 33) . The mechanisms underlying these results may involve the production of y-interferon (34) and the differentiation of HSV-specific cytotoxic T cells (35) , both of which are mediated by T helper cells. Thus, our demonstration that HSV gD synthetic peptides activate these cells in vitro may reflect the potential of synthetic peptide 1-23 as a T-cell-directed immunoadjuvant in adults.
The T-cell lines derived from children's PBMC stimulated with synthetic peptide and supplemented with IL-2 were found to be qualitatively different from the adult lines. Whereas most adult lines responded in a dose-dependent fashion to 1-23(H) and other analogs, no specific proliferative response was detected with the children's lines. Despite the lack of antigen-induced proliferation by the children's lines, 1-23(H) was most likely responsible for their induction, since the ability of T cells to grow in IL-2 is dependent on prior activation with antigen (36) and lack of restimulation with antigen resulted in total death of these lines after 10-12 days with IL-2 alone (data not shown).
The phenotypes of the major population (Leu-1-and -2-positive; DR-positive) suggest that these cells may be suppressor effectors (37) . Indeed, a recent report shows that suppressor T cells are induced in neonatal mononuclear cell cultures at antigen concentrations that induce helper cells in adult cultures (38) . The suppressor cells' inability to proliferate in response to antigen is analogous to murine suppressor effector T-cell lines against human gamma globulin, shown by Levich et al. (39) to be inducible by but nonresponsive to human gamma globulin in a proliferation assay.
The presence of low but significant numbers of phenotypic NK cells in adult lines and even higher proportions of these cells in activated lines from seronegative children suggests that 1-23(H) may induce NK activation, as shown with mature native HSV gD (40) . Alternatively, NK cells in these cultures may have been activated by y-interferon, which is known to be produced by activated T cells in vitro (41) and to stimulate human NK cells (42) .
In conclusion, peptides of HSV gD can activate antigenspecific T cells in vitro from adults whether or not these donors have serum antibody to HSV. T-cell lines from seronegative children were also induced by this molecule but did not proliferate in response to any fragment tested. The function of these cells and their relevance to protection against HSV await further determination.
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